CB Scientific, Inc. announced that the company has developed a novel product medical device portfolio since acquiring Marutronics Medical Devices in February 2017. The company has developed three core platform technologies; CannaRAPID™, CannaNASAL™, and CannaDERME™, focused on precise dosing and controlled release of cannabinoid compounds for patients. CB Scientific's will be launching CannaRAPID, a sublingual cannabinoid delivery product, at the end of May 2017. There are several inherent benefits of sublingual delivery of drugs such as fast absorption, avoidance of unwanted liver and gut microbiota metabolism on active drug. Further, as medical cannabis is going to be on mainstream medicine, there is an urgent need for a new dosage and delivery form that can improve patient compliance. Common complaints about the difficulty in swallowing tablets in the order of frequency of complaints are size, surface, form, and taste of tablets are common in various patient groups. Geriatric and pediatric patients and traveling patients who may not have ready access to water are most in need of easy swallowing dosage forms. CB Scientific's sublingual product, CannaRAPID is a sugar-free Orally Disintegrating Tablet to deliver precise dose cannabinoids to neural tissues in a matter of seconds. The formulation is optimized with nanotechnology and tissue permeation enhancing molecules for faster absorption. CB Scientific is pairing up with clinical organizations and various clinical practitioners for conducting clinical studies using CannaRAPID for various indications such as stress and anxiety relief, cognitive focus, various kinds of pain, migraines etc.